Objective. Correlation between radiologic structural abnormalities and clinical symptoms in low back pain patients is poor. There is an unmet clinical need to image inflammation in pain conditions to aid diagnosis and guide treatment. Ferumoxytol, an ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle, is clinically used to treat iron deficiency anemia and showed promise in imaging tissue inflammation in human. We explored whether ferumoxytol can be used to identify tissue and nerve inflammation in pain conditions in animals and humans.
Methods. Complete Freud's adjuvant (CFA) or saline was injected into mice hind paws to establish an inflammatory pain model. Ferumoxytol (20 mg/kg) was injected intravenously. Magnetic resonance imaging (MRI) was performed prior to injection and 72 hours postinjection. The changes in the transverse relaxation time (T2) before and after ferumoxytol injection were compared between mice that received CFA vs saline injection. In the human study, we administered ferumoxytol (4 mg/kg) to a human subject with clinical symptoms of lumbar radiculopathy and compared the patient with a healthy subject.
Results. Mice that received CFA exhibited tissue inflammation and pain behaviors. The changes in T2 before and after ferumoxytol injection were significantly higher in mice that received CFA vs saline (20.8 6 3.6 vs 2.2 6 2.5, P 5 0.005). In the human study, ferumoxytolenhanced MRI identified the nerve root corresponding to the patient's symptoms, but the nerve root was not impinged by structural abnormalities, suggesting the potential superiority of this approach over conventional structural imaging techniques.
Conclusions. Ferumoxytol-enhanced MRI can identify tissue and nerve inflammation and may provide a promising diagnostic tool in assessing pain conditions in humans.
Introduction
Inflammation underlies many common clinical pain conditions, such as joint pain in rheumatoid arthritis and low back pain in lumbar spondylosis and radiculopathy. However, diagnosing these pain conditions is challenging. Many radiologic abnormalities found in low back pain (LBP) patients are also present in asymptomatic individuals, and many patients with LBP and/or sciatica have no identifiable radiologic abnormalities. Furthermore, structural imaging does not capture functional biological processes leading to pain. Therefore, correlation between radiologic abnormalities and clinical symptoms remains poor [1, 2] . Thus, there is an unmet clinical need to image inflammation in pain conditions to aid in diagnosis and to guide treatment, especially for patients with sciatica.
Macrophage and monocyte infiltration is a hallmark of tissue inflammation. These inflammatory cells are seen in joint arthritis and nerve root inflammation. Ferumoxytol is an iron product that has been approved by the US Food and Drug Administration to treat iron deficiency anemia. It is composed of ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles that are taken up by the macrophage-monocyte system. Iron oxide nanoparticles can alter magnetic resonance imaging (MRI) signals by shortening the transverse relaxation times (T2) of protons, leading to signal changes quantifiable by MRI, even if the microscopic distribution is below the resolution threshold [3] . This property has been explored in experimental settings to track cells and image tumors. Ferumoxytollabeled human neural progenitor cells can be tracked upon transplantation into the porcine spinal cord [4] . These cells can be identified with MRI for up to 105 days after transplantation. In a mouse model of human glioblastoma, MRI with ferumoxytol reveals monocyte infiltration into the tumor [5] , a key prognostic factor in determining treatment response.
In this report, we sought to examine whether ferumoxytol MRI can be used to image tissue and nerve inflammation in an experimental animal pain model and in humans with lumbar radicular pain.
Methods

Animals
All procedures and animal use were approved by the Massachusetts General Hospital (MGH) Institutional Animal Care and Use Committee (IACUC) and were in accordance with the guidelines established by the National Institutes of Health and the International Association for the Study of Pain. Male C57BL/6 mice age five to seven weeks were purchased from Charles River Laboratories and were kept in a specific pathogen-free environment with a 12-hour light (7:00 to 19:00) and 12-hour dark (19:00-7:00) cycle. Animals were supplied with food and water ad libitum.
Human Subjects
After institutional review board approval, we recruited two human subjects, including a healthy subject and a pain subject with a history of chronic right lower extremity radicular pain. The healthy subject is a 34-year-old male with no pain complaints. The pain subject is a 52-yearold male with a history of intermittent low back pain radiating to the left posterior thigh and leg for 15 years, which had subsided for three months at the time of imaging. He also has a four-year history of right groin and anteromedial thigh pain, which was his main pain complaint at the time of imaging. His right groin and anteromedial thigh pain had responded well to a previous right L3 transforaminal epidural steroid injection two and half years before but had recurred at the time of study. No further treatment was sought after due to his insurance issues.
Medication
Ferumoxytol injection was purchased from the manufacturer AMAG Pharmaceuticals (Waltham, MA, USA) via our institutional research pharmacy.
Inflammatory Pain Model
To induce long-term inflammation, a single 10-lL injection of 1-mg/mL complete Freud's adjuvant (CFA; Sigma Aldrich, St. Louis, MO, USA) was injected into the plantar hind paw. Mice were anesthetized with isoflurane briefly for the injection. A single intraplantar injection of CFA in this location has been demonstrated to induce a rheumatoid arthritis-like pathology in the hind paw of C57BL/6 mice. Controls were injected in the same location with 10 lL of normal saline (Hospira, IL, USA).
Hind Paw Thickness Measurements
Hind paw thickness was measured using digital calipers (Neiko 01407 A, Neiko Tools, Shenyang, China). Mice were carefully handled, and hind paws were approached by digital caliper at the level of the metatarsal joint. The caliper was placed in contact with skin without pressure.
Behavioral Testing
Mechanical hind paw withdrawal thresholds were determined by the Up-Down method [6] . Habituation was performed prior to behavioral tests. Mice were brought to the testing room and placed on the testing platform for about 15 to 30 minutes two days prior to and one day prior to the testing day to ensure environmental familiarity and minimize anxiety-induced behavioral changes confounding mechanical withdrawal. Von Frey filaments were used to determine mechanical thresholds, and a threshold was established by at least two hind paw withdrawal responses out of five tests. Experimenters were blinded to the group assignments.
Cell Isolation from Footpad
Three days after CFA injection, mice were euthanized and then perfused with 40 mL of ice-cold normal saline solution through the left ventricle cannulation to minimize circulating red blood cell and white blood cell contamination. Total hind paw tissue following removal of the toes and bones was incubated at 37 C for 90minutes in 3 mL of Dulbecco's modified Eagle medium (DMEM) containing 160 lg/mL of Liberase TL purified enzyme blend (Roche Diagnostic Corp.). Following Liberase treatment, tissue was homogenized with 10 mL of RPMI medium containing 0.05% DNase (Stemcell Technologies), and the homogenate was filtered with a 50-lm-pore-size cell strainer. Cell pellets were made by centrifugation using 370 g Â 7 min followed by resuspension in 5 mL of RPMI medium. A two-layer Percoll (Sigma-Aldrich) density gradients: 40% Percoll over 70% Percoll was used for leukocyte sedimentation at 2560 g for 11 minutes.
Flow Cytometry
Cells were washed with FACS buffer (PBS with 2% fetal calf serum and 0.1% NaN3), and cell surface stainings were performed at 4 C for 30 minutes using the following antimouse antibodies from BioLegend: CD11b Pacific Blue (101223), F4/80 Alexa488 (246796), CD3 PE(100205). A Fc receptor block step with antimouse CD16/32 (BioLegend 101319) was performed to minimize nonspecific bindings of antibodies. Samples were acquired with LSR-II (BD) flow analyzer. Data were analyzed with FlowJo software (FlowJo).
Mice MRI Imaging
Mice were first imaged three days post-CFA. Following the baseline MRI, mice were administered 20 mg/kg of ferumoxytol intravenously. The second MRI was performed 72 hours after the ferumoxytol administration. Mice were anesthetized with 1-2% isoflurane gas in oxygen throughout the scan with respiratory monitoring. Mice were imaged on a Bruker 4.7 Tesla MRI scanner. T2-mapping images were acquired using the multislice multi-echo (MSME) sequence with a TR ¼ 2316 ms, four averages, 128 Â 128 Â 16 matrix size, 0.313 Â 0.313 Â 0.6 mm voxel size sequence with 16 echos with 8.68-ms echo spacing. In addition, T2-weighted images were obtained using the rapid acquisition with refocused 
Human MR Imaging
Each subject underwent two lumbar spine MRI sessions: one at baseline and one 48 hours after ferumoxytol administration. We elected to perform the postferumoxytol MR scan at 48 hours after administration based on a recent human study showing optimal imaging at this time point after ferumoxytol administration [7] . Lumbar MRI was acquired on a 1.5T scanner (GE) using an eightchannel CTL spine coil. Sagittal T2-weighted 3D images (CUBE) were acquired with the following parameters: TR ¼ 1500 ms, TE ¼ 101 ms, field of view (FOV) ¼ 24 cm, matrix size ¼ 224 Â 224 Â 144. The CUBE images were subsequently reconstructed to obtain axial and coronal images. Axial and sagittal T2 mapping experiments were conducted using TR ¼ 1000 ms, TE ¼ 5.3, 10.6, 15.9, 21.2, 26.5, 31.8, 37.1, 42.4 ms, FOV ¼ 21 cm, matrix size ¼ 256 Â 192. T2 mapping images were then curvefitted to an exponential decay equation to obtain T2 maps. T2*-weighted imaging was performed with a 3D gradient echo sequence with the following parameters: TR ¼ 43, TE ¼ 12, flip angle ¼ 5, FOV ¼ 18 cm, matrix size ¼ 256 Â 128 Â 128. Following the baseline MRI session, ferumoxytol at a dose of 4 mg/kg diluted in 250 mL of normal saline was infused intravenously over 30 minutes under MD supervision. Forty-eight hours after ferumoxytol administration, the subjects underwent MR imaging with the same sequences.
Image Interpretation
Human MR images were interpreted by two boardcertified neuroradiologists blinded to subjects' clinical conditions (healthy or pain subject, pain symptoms). Mouse MR images were interpreted by investigators blinded to the group assignment of the mice.
Statistics
Animal behavior data and paw thickness were analyzed using one-way analysis of variance with repeated measures. Monocyte and macrophage comparison was analyzed with the Student's t test. Animal MRI T2 values were analyzed using the Student's t test.
Results
Inflammatory Pain Model
We randomized C57BL/6 mice into a CFA group and a saline (control) group. We examined the hind paw mechanical withdrawal thresholds at different time points after the injection. While the two groups did not exhibit differences in their baseline mechanical withdrawal thresholds, mice in the CFA group displayed significantly lower mechanical withdrawal thresholds than mice in saline group at each of the time points postinjection ( Figure 1A ). The lower mechanical withdrawal thresholds indicate the development of pain behavior secondary to CFA injection. We also compared the hind paw thicknesses between mice in the CFA with those in the saline group. Mice in the CFA group were noted to have significant hind paw and ankle swelling after injection, and their hind paws were significantly thicker than those of mice in the saline group ( Figure 1B) . Therefore, CFA group mice displayed increased hind paw tissue swelling as measured by paw thickness, and pain behavior as indicated by significantly reduced mechanical withdrawal thresholds. These results are consistent with previous reports that CFA hind paw injection elicits tissue inflammation and inflammatory pain [8, 9] .
We next examined whether there is an influx of macrophages and monocytes during the development of hind paw inflammatory pain. Hind paw tissue from mice in both CFA and saline groups was digested; infiltrating cells were isolated and stained for cell surface markers ( Figure 1C) . Numbers of both F4/80þ CD11bþ macrophages and F4/80-CD11bþ monocytes were significantly higher in the CFA group than in the saline group ( Figure 1D ). (A) Noncontrast MRI was performed at day 3 post-CFA and saline injection. Immediately after the MRI, ferumoxytol was administered to these mice, followed by MRI at 48 hours after ferumoxytol administration. MRI images represent four mice from each group. (B) Changes in T2 before and after ferumoxytol were calculated. CFA group showed significantly higher changes in T 2 than saline group.
Ferumoxytol MRI Reports Inflammation Related to Pain
Seventy-two hours after ferumoxytol injection, mice injected with CFA demonstrated marked signal loss on T2-weighted imaging ( Figure 2A ) compared with control mice injected with saline. Moreover, the T2 mapping experiment in these mice showed that in mice with CFAinduced pain, T2 change was significantly higher than that in control mice without CFA (20.8 63.6 vs 2.2 6 2.5, mean 6 SE, P ¼ 0.005) ( Figure 2B ), confirming that ferumoxytol accumulated in the CFA-inflamed tissue but not in the uninflamed tissue.
Human Imaging on Neuroinflammation
In the pain subject, the T2-weighted signal showed a substantial change after ferumoxytol administration around the right L3 nerve root as it exits the neural foramen ( Figure 3A , only T2-weighted images shown; T2*-weighted images had susceptibility artifact in this location) and as it descends within the spinal canal ( Figure 3B , T2*-weighted images shown.), indicating inflammation around the nerve root. This change in T2*-weighted signals after ferumoxytol was not present on the left side, where the subject has no pain symptoms ( Figure 3A) . Interestingly, even though there were structural abnormalities interpreted by the neuroradiologists in this subject, such as a small disc protrusion touching on the exiting right L4 nerve root and narrowing of the subarticular zone touching on the right descending L5 nerve roots at the L4/5 level, there was no noticeable T2* signal change after ferumoxytol administration at these levels ( Figure 3C ). Importantly, the presence of reduced T2* signals around the right L3 nerve root, suggesting an inflammatory process, is concordant with the subject's clinical presentation of right-sided groin and anteromedial thigh pain symptoms. Therefore, ferumoxytol MRI was able to differentiate the "culprit" nerve root from other nerve roots. As expected, in the healthy subject with no pain symptoms, no signal changes around any spinal nerve roots were identified ( Figure 4 ).
Discussion
In this report, using an inflammatory pain animal model, we demonstrate that ferumoxytol MRI reveals tissue inflammation, which is not feasible with conventional MRI. In addition, proof-of-concept human study indicate that ferumoxytol MRI can identify the symptomatic neuronal tissue inflammation in lumbar radiculopathy.
Pain has traditionally been categorized into neuropathic pain and inflammatory pain [10] . Neuropathic pain and inflammatory pain respond to treatment differently. Many pain conditions, including lumbar radiculopathy secondary to intervertebral disc protrusion, can have prominent inflammatory component [11, 12] . Epidural steroid injections (ESIs), delivering potent anti-inflammatory steroid medications to the epidural space where spinal nerve roots are located, are widely used to treat radicular pain, with varying degrees of success and also potential complications [13] [14] [15] [16] . However, not all radicular pain responds to ESIs. Patients with radicular pain who do not benefit from epidural steroid injections may respond to neuropathic pain medications, suggesting inflammation may not be the only process leading to radicular pain. Thus it would be extremely valuable to determine whether inflammation is present in radicular pain before proceeding with ESIs. The ability to detect nerve root inflammation in vivo can provide crucial guidance to the treatment pathway selection.
Ferumoxytol is clinically used to treat iron deficiency anemia. Off-label use of ferumoxytol as an MRI contrast agent has been reported as an alternative to gadolinium-based contrast agent [17] . For example, for patients with end-stage renal disease, ferumoxytol is used because it does not cause nephrogenic systemic fibrosis. Unlike gadolinium-based agents, which are nonspecific and do not reliably report tissue inflammation, ferumoxytol has been found to label infiltrating monocytes and macrophages in mouse glioblastoma [18] , a critical prognostic factor for chemotherapy treatment response. In type 1 diabetes, the activation of mononuclear phagocytes is a critical factor in disease onset and progression. Nanoparticle-based MRI technology has provided major technological advancement in imaging pancreatic inflammation. Gaglia et al. recently showed that ferumoxytol MRI enables imaging of macrophage infiltration in the pancreas and leads to high-resolution mapping of pancreatic inflammation in type 1 diabetes patients [7, 19] .
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Postferumoxytol Postferumoxytol Preferumoxytol Preferumoxytol L3/4 L4/5 Figure 4 Ferumoxytol-contrasted magnetic resonance imaging (MRI) in a healthy subject. A subject without any pain symptoms underwent MR imaging study using the same protocol as pain subject. Upper panels were MR images; lower panels were heat map-coded MR images. There were no significant disc protrusions identified by conventional MR images. Heat map-coded MR images did not reveal signal strength changes around nerve roots before and after ferumoxytol administration.
In this report, we took advantage of the uptake of USPIO by the macrophage-monocyte system and the subsequent signal loss effect on T2-weighted MR images to identify tissue inflammation. In an animal model of inflammatory pain caused by joint arthritis after CFA injection, we demonstrated that ferumoxytol-contrasted MRI can show significant changes in T2, consistent with inflammatory macrophage and monocyte infiltration in the tissue and the uptake of ferumoxytol by these cells. In this proof-ofconcept human MRI study, we demonstrated that ferumoxytol MRI showed a loss of T2-weighted signal in a spinal nerve root that is concordant with the subject's pain symptoms and clinical diagnosis, whereas structural abnormalities identified by conventional MRI had no correlation. Taken together, this study suggests that USPIO, such as ferumoxytol, may be able to detect pain-inducing inflammation in humans in vivo. This imaging approach may be superior to conventional structural MRI in identifying the anatomical source of pain caused by inflammation and providing guidance to interventional treatments. While results from this pilot animal study and single-patient clinical study are encouraging, future studies with more human subjects are warranted to examine the utility of ferumoxytol MRI in diagnosing different pain conditions in a large patient cohort.
